Company Overview

STERIS plc is a leading global provider of products and services designed to support patient care with a primary focus on infection prevention. Headquartered in Mentor, Ohio, and domiciled in Ireland, the company operates as the global leader in contract sterilization services. This crucial role ensures the safe delivery of single-use and implantable medical equipment to hospitals and healthcare providers worldwide.

Business Overview

STERIS operates through three distinct segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The revenue breakdown highlights the company's primary focus areas: approximately 70% is derived from the Healthcare segment, 19% from Applied Sterilization Technologies, and 11% from Life Sciences services.

Healthcare Segment

This segment offers a comprehensive range of solutions including cleaning chemistries and sterility assurance products. It also provides automated endoscope reprocessing systems and tracking products, endoscopy accessories, washers, sterilizers, and other capital equipment essential for the operation of sterile processing departments. Furthermore, the segment supplies equipment used directly in procedure rooms, such as surgical tables, lights, and connectivity solutions.

Applied Sterilization Technologies (AST)

The AST segment is dedicated to providing contract sterilization and testing services. These services cater to medical device and pharmaceutical manufacturers and are delivered through a global network of contract sterilization and laboratory facilities. The segment also includes integrated sterilization equipment and control systems.

Life Sciences

The Life Sciences segment focuses on the design, manufacturing, and sale of consumable products. This includes pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical-grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high-purity water and pure steam generators.

Financial Performance and Market Position

STERIS's financial performance demonstrates its robust position in the healthcare technology sector. As of September 2025, with STERIS stock trading at $227.50 per share, the company's market capitalization stands at $22.35 billion. This valuation is based on approximately 98,250,789 outstanding shares.

Fiscal Year 2025 Results

For fiscal year 2025, STERIS reported revenue from continuing operations increased by 6% to $5.5 billion, up from $5.1 billion in fiscal year 2024. The full-year reported diluted Earnings Per Share (EPS) from continuing operations rose to $6.16, while the adjusted EPS per diluted share reached $9.22.

Recent Quarterly Performance (Q1 Fiscal 2026)

For the first quarter of fiscal year 2026 (ended June 30, 2025):

- Total Revenue: Increased by 8% to $1.3 billion, compared to $1.2 billion in Q1 fiscal 2025.

- Healthcare Revenue: Grew by 10% to $901.2 million, driven by a 23% increase in consumables and a 14% increase in services.

- Applied Sterilization Technologies (AST) Revenue: Increased by 7% to $249.8 million.

- Adjusted EPS: Grew to $2.03 in Q1 fiscal 2025, an improvement from $1.84 in the same quarter of the previous year.

Key Financial Metrics

- Market Capitalization: $22.35 Billion (as of September 2025)

- Stock Price: $227.50 (as of September 2025)

- Total Employees: 17,787 globally

- Fiscal Year 2025 Revenue: $5.5 Billion

- Fiscal Year 2025 Adjusted EPS: $9.22

- Q1 FY2026 Revenue: $1.3 Billion

- Q1 FY2026 Adjusted EPS: $2.03

Business Operations and Production Capacity

STERIS operates a global network of facilities dedicated to contract sterilization and laboratory testing services, supporting medical device and pharmaceutical manufacturers. Its business operations are segmented into Healthcare, Applied Sterilization Technologies (AST), and Life Sciences, each serving critical needs within their respective markets.

Product Portfolio and Market Strategy

STERIS's product portfolio is strategically diversified across its three segments, providing stability and diverse growth avenues. The company's market strategy is centered on delivering mission-critical products and services that are indispensable for infection prevention in healthcare settings.

Future Growth Plans and Strategic Initiatives

STERIS is focused on providing essential products and services that underpin infection prevention within healthcare environments. The company actively pursues expansion of its global footprint through a combination of organic growth initiatives and strategic acquisitions.

Growth Opportunities

- Recurring Revenue Streams: Expansion in recurring consumables and services, coupled with a strong focus on regulatory compliance, enhances margin visibility and positions the company for stable, long-term earnings growth.

- Secular Demand & Innovation: Secular demand trends in healthcare and life sciences, combined with an innovation-driven portfolio strategy, support top-line growth and market share gains in both developed and emerging markets.

Corporate Information

STERIS was founded in 1985. While headquartered in Mentor, Ohio, the company is domiciled in Ireland. STERIS trades on the New York Stock Exchange under the ticker symbol STE. The company's 52-week trading range has been between a high of $248.24 and a low of $200.98.